Pliant Therapeutics, Inc.

PLRX Healthcare Biotechnology

Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022. In the quarter to June 2026, EPS grew 49.3% and free cash flow grew 68.6%, each against the same quarter a year earlier.

0.90 0.07 −7.22%
Market cap
$60.2M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
4/9
Altman Z
15.11
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
13.93 12.00 16.89 9.90
Net Debt/EBITDA
7.69 8.33 8.10 6.66
Debt/Equity
0.15 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.34) (0.29) (0.31) (0.21)
Book value per Share
3.26 2.95 2.67 2.37
Free Cash Flow
(20.92) (17.79) (19.13) (12.78)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates